Sage plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s after it failed to boost cognitive function in a Phase 2 ...

Are you seeing a lot of pink lately? You probably have, since October is internationally recognized as Breast Cancer Awareness Month. Just as purple is associated with Alzheimer’s disease, pink ...

Patients with Alzheimer’s disease (AD) experience a slow progressive decline in memory and cognitive ability, among other symptoms, due to the spread of damage in the brain. Generally, the disease is ...

While Alzheimer’s disease (AD) has no cure, five prescription medicines have been approved by the U.S. Food and Drug Administration (FDA) to treat disease symptoms that impact thinking and memory.

The approved drugs for Alzheimer’s disease do not address the underlying cause of the disease, but instead treat only the symptoms. However, there is a vast array of experimental treatments that are ...

Researchers evaluated the link between nighttime light pollution in the U.S. and how common Alzheimer’s is based on Medicare ...

September is awareness month for Alzheimer’s disease and other forms of dementia, and Alzheimer’s Disease International (ADI) is calling on the disease to be made a global health priority with the ...

After completing a third review of interim safety data, an independent safety monitoring board has recommended the continuation — without modifications — of two ongoing Phase 3 clinical trials testing ...

If you’re diagnosed with dementia or its most common form, Alzheimer’s disease, please know that however you feel about it is how you feel about it. Your feelings are valid. Someone diagnosed with ...

Alzheimer’s disease is a progressive neurodegenerative disorder and the most common cause of dementia. It most often emerges during a person’s mid-60s or older, although early-onset varieties exist.